BillionToOne is expected to report Q3 2026 revenue of $116.27 million and EPS of $0.16, with shares currently trading at $114.84 compared to an analyst target of $125.00.
Investors are primarily focused on the growth of oncology clinical testing revenue as the company expands its liquid biopsy portfolio.
The report follows a volatile second quarter where shares plummeted nearly 30% after management maintained rather than raised annual guidance despite a significant earnings beat.
Markets are now seeking a guidance revision and confirmation that recent milestones, including the Epic Aura integration and an expanded Anthem contract, are driving accelerated test volume across the UNITY and Northstar platforms.